Central Role of Defective Interleukin-2 Production in the Triggering of Islet Autoimmune Destruction

Immunity

Volumn 28, Issue 5, 2008, Pages 687-697

  Tang, Qizhi ^a   Adams, Jason Y ^a   Penaranda, Cristina ^a   Melli, Kristin ^a   Piaggio, Eliane ^b   Sgouroudis, Evridiki ^c   Piccirillo, Ciriaco A ^c   Salomon, Benoit L ^b   Bluestone, Jeffrey A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SORBONNE UNIVERSITÉ   (France)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

CELLIMMUNO; MOLIMMUNO

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; PROTEIN BCL 2;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; CELL SURVIVAL; DISEASE COURSE; IMMUNOLOGICAL TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

ANIMALS; AUTOIMMUNITY; CD4-POSITIVE T-LYMPHOCYTES; CELL SURVIVAL; DIABETES MELLITUS, TYPE 1; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; ISLETS OF LANGERHANS; LYMPH NODES; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED NOD; PROTO-ONCOGENE PROTEINS C-BCL-2; T-LYMPHOCYTES, REGULATORY;

EID: 43049174722     PISSN: 10747613     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.immuni.2008.03.016     Document Type: Article

References (61)

1. Aluvihare V.R., and Betz A.G. The role of regulatory T cells in alloantigen tolerance. Immunol. Rev. 212 (2006) 330-343
2. Anderson M.S., and Bluestone J.A. The NOD mouse: a model of immune dysregulation. Annu. Rev. Immunol. 23 (2005) 447-485
3. Arkwright P.D., Abinun M., and Cant A.J. Autoimmunity in human primary immunodeficiency diseases. Blood 99 (2002) 2694-2702
4. Belkaid Y., Blank R.B., and Suffia I. Natural regulatory T cells and parasites: a common quest for host homeostasis. Immunol. Rev. 212 (2006) 287-300
5. Belkaid Y., Piccirillo C.A., Mendez S., Shevach E.M., and Sacks D.L. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 420 (2002) 502-507
6. Bour-Jordan H., Salomon B.L., Thompson H.L., Szot G.L., Bernhard M.R., and Bluestone J.A. Costimulation controls diabetes by altering the balance of pathogenic and regulatory T cells. J. Clin. Invest. 114 (2004) 979-987
7. Boyman O., Kovar M., Rubinstein M.P., Surh C.D., and Sprent J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 311 (2006) 1924-1927
8. Brusko T.M., Wasserfall C.H., Clare-Salzler M.J., Schatz D.A., and Atkinson M.A. Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes. Diabetes 54 (2005) 1407-1414
9. Chatenoud L. CD3 antibody treatment stimulates the functional capability of regulatory T cells. Novartis Found. Symp. 252 (2003) 279-286
10. Chen Z., Herman A.E., Matos M., Mathis D., and Benoist C. Where CD4+CD25+ T reg cells impinge on autoimmune diabetes. J. Exp. Med. 202 (2005) 1387-1397
11. Chentoufi A.A., and Polychronakos C. Insulin expression levels in the thymus modulate insulin-specific autoreactive T-cell tolerance: the mechanism by which the IDDM2 locus may predispose to diabetes. Diabetes 51 (2002) 1383-1390
12. D'Cruz L.M., and Klein L. Development and function of agonist-induced CD25+Foxp3+ regulatory T cells in the absence of interleukin 2 signaling. Nat. Immunol. 6 (2005) 1152-1159
13. Denny P., Lord C.J., Hill N.J., Goy J.V., Levy E.R., Podolin P.L., Peterson L.B., Wicker L.S., Todd J.A., and Lyons P.A. Mapping of the IDDM locus Idd3 to a 0.35-cM interval containing the interleukin-2 gene. Diabetes 46 (1997) 695-700
14. Dupuis-Girod S., Medioni J., Haddad E., Quartier P., Cavazzana-Calvo M., Le Deist F., de Saint Basile G., Delaunay J., Schwarz K., Casanova J.L., et al. Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients. Pediatrics 111 (2003) e622-e627
15. Fisher R.I., Rosenberg S.A., and Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J. Sci. Am. 6 Suppl 1 (2000) S55-S57
16. Fontenot J.D., Rasmussen J.P., Gavin M.A., and Rudensky A.Y. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat. Immunol. 6 (2005) 1142-1151
17. Fontenot J.D., Rasmussen J.P., Williams L.M., Dooley J.L., Farr A.G., and Rudensky A.Y. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 22 (2005) 329-341
18. Furtado G.C., Curotto de Lafaille M.A., Kutchukhidze N., and Lafaille J.J. Interleukin 2 signaling is required for CD4(+) regulatory T cell function. J. Exp. Med. 196 (2002) 851-857
19. Garchon H.J., Luan J.J., Eloy L., Bedossa P., and Bach J.F. Genetic analysis of immune dysfunction in non-obese diabetic (NOD) mice: mapping of a susceptibility locus close to the Bcl-2 gene correlates with increased resistance of NOD T cells to apoptosis induction. Eur. J. Immunol. 24 (1994) 380-384
20. Gregori S., Giarratana N., Smiroldo S., and Adorini L. Dynamics of pathogenic and suppressor T cells in autoimmune diabetes development. J. Immunol. 171 (2003) 4040-4047
21. Horak I., Lohler J., Ma A., and Smith K.A. Interleukin-2 deficient mice: a new model to study autoimmunity and self-tolerance. Immunol. Rev. 148 (1995) 35-44
22. Huehn J., Siegmund K., Lehmann J.C., Siewert C., Haubold U., Feuerer M., Debes G.F., Lauber J., Frey O., Przybylski G.K., et al. Developmental stage, phenotype, and migration distinguish naive- and effector/memory-like CD4+ regulatory T cells. J. Exp. Med. 199 (2004) 303-313
23. Knoechel B., Lohr J., Kahn E., Bluestone J.A., and Abbas A.K. Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. J. Exp. Med. 202 (2005) 1375-1386
24. Korn T., Reddy J., Gao W., Bettelli E., Awasthi A., Petersen T.R., Backstrom B.T., Sobel R.A., Wucherpfennig K.W., Strom T.B., et al. Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat. Med. 13 (2007) 423-431
25. Krysko D.V., D'Herde K., and Vandenabeele P. Clearance of apoptotic and necrotic cells and its immunological consequences. Apoptosis 11 (2006) 1709-1726
26. Kukreja A., Cost G., Marker J., Zhang C., Sun Z., Lin-Su K., Ten S., Sanz M., Exley M., Wilson B., et al. Multiple immuno-regulatory defects in type-1 diabetes. J. Clin. Invest. 109 (2002) 131-140
27. Lindley S., Dayan C.M., Bishop A., Roep B.O., Peakman M., and Tree T.I. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 54 (2005) 92-99
28. Makino S., Kunimoto K., Muraoka Y., Mizushima Y., Katagiri K., and Tochino Y. Breeding of a non-obese, diabetic strain of mice. Jikken Dobutsu 29 (1980) 1-13
29. Miyazaki T., Liu Z.J., Kawahara A., Minami Y., Yamada K., Tsujimoto Y., Barsoumian E.L., Permutter R.M., and Taniguchi T. Three distinct IL-2 signaling pathways mediated by bcl-2, c-myc, and lck cooperate in hematopoietic cell proliferation. Cell 81 (1995) 223-231
30. Mombaerts P., Mizoguchi E., Grusby M.J., Glimcher L.H., Bhan A.K., and Tonegawa S. Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice. Cell 75 (1993) 275-282
31. Munn D.H., and Mellor A.L. The tumor-draining lymph node as an immune-privileged site. Immunol. Rev. 213 (2006) 146-158
32. Nakayama M., Abiru N., Moriyama H., Babaya N., Liu E., Miao D., Yu L., Wegmann D.R., Hutton J.C., Elliott J.F., and Eisenbarth G.S. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 435 (2005) 220-223
33. Pandiyan P., Zheng L., Ishihara S., Reed J., and Lenardo M.J. CD4(+)CD25(+)Foxp3(+) regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4(+) T cells. Nat. Immunol. 8 (2007) 1353-1362
34. Pop S.M., Wong C.P., Culton D.A., Clarke S.H., and Tisch R. Single cell analysis shows decreasing FoxP3 and TGFbeta1 coexpressing CD4+CD25+ regulatory T cells during autoimmune diabetes. J. Exp. Med. 201 (2005) 1333-1346
35. Prochazka M., Leiter E.H., Serreze D.V., and Coleman D.L. Three recessive loci required for insulin-dependent diabetes in nonobese diabetic mice. Science 237 (1987) 286-289
36. Putnam A.L., Vendrame F., Dotta F., and Gottlieb P.A. CD4+CD25high regulatory T cells in human autoimmune diabetes. J. Autoimmun. 24 (2005) 55-62
37. Qin H.Y., and Singh B. BCG vaccination prevents insulin-dependent diabetes mellitus (IDDM) in NOD mice after disease acceleration with cyclophosphamide. J. Autoimmun. 10 (1997) 271-278
38. Rabinovitch A., Suarez-Pinzon W.L., Shapiro A.M., Rajotte R.V., and Power R. Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice. Diabetes 51 (2002) 638-645
39. Rietz C., Screpanti V., Brenden N., Bohme J., and Fernandez C. Overexpression of bcl-2 in T cells affects insulitis in the nonobese diabetic mouse. Scand. J. Immunol. 57 (2003) 342-349
40. Rouse B.T., Sarangi P.P., and Suvas S. Regulatory T cells in virus infections. Immunol. Rev. 212 (2006) 272-286
41. Sakaguchi S., Ono M., Setoguchi R., Yagi H., Hori S., Fehervari Z., Shimizu J., Takahashi T., and Nomura T. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol. Rev. 212 (2006) 8-27
42. Salomon B., Lenschow D.J., Rhee L., Ashourian N., Singh B., Sharpe A., and Bluestone J.A. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 12 (2000) 431-440
43. Setoguchi R., Hori S., Takahashi T., and Sakaguchi S. Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J. Exp. Med. 201 (2005) 723-735
44. Sharif S., Arreaza G.A., Zucker P., Mi Q.S., Sondhi J., Naidenko O.V., Kronenberg M., Koezuka Y., Delovitch T.L., Gombert J.M., et al. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat. Med. 7 (2001) 1057-1062
45. Sheu B.C., Hsu S.M., Ho H.N., Lien H.C., Huang S.C., and Lin R.H. A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res. 61 (2001) 237-242
46. Shi F.D., Flodstrom M., Balasa B., Kim S.H., Van Gunst K., Strominger J.L., Wilson S.B., and Sarvetnick N. Germ line deletion of the CD1 locus exacerbates diabetes in the NOD mouse. Proc. Natl. Acad. Sci. USA 98 (2001) 6777-6782
47. Tang Q., Adams J.Y., Tooley A.J., Bi M., Fife B.T., Serra P., Santamaria P., Locksley R.M., Krummel M.F., and Bluestone J.A. Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat. Immunol. 7 (2006) 83-92
48. Tang Q., and Bluestone J.A. Regulatory T-cell physiology and application to treat autoimmunity. Immunol. Rev. 212 (2006) 217-237
49. Tang Q., Henriksen K.J., Bi M., Finger E.B., Szot G., Ye J., Masteller E.L., McDevitt H., Bonyhadi M., and Bluestone J.A. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J. Exp. Med. 199 (2004) 1455-1465
50. Tang Q., Henriksen K.J., Boden E.K., Tooley A.J., Ye J., Subudhi S.K., Zheng X.X., Strom T.B., and Bluestone J.A. Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J. Immunol. 171 (2003) 3348-3352
51. Taniguchi T., Matsui H., Fujita T., Takaoka C., Kashima N., Yoshimoto R., and Hamuro J. Structure and expression of a cloned cDNA for human interleukin-2. Nature 302 (1983) 305-310
52. Todd J.A., Bell J.I., and McDevitt H.O. HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature 329 (1987) 599-604
53. Todd J.A., and Wicker L.S. Genetic protection from the inflammatory disease type 1 diabetes in humans and animal models. Immunity 15 (2001) 387-395
54. Ueda H., Howson J.M., Esposito L., Heward J., Snook H., Chamberlain G., Rainbow D.B., Hunter K.M., Smith A.N., Di Genova G., et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423 (2003) 506-511
55. Villarino A.V., Tato C.M., Stumhofer J.S., Yao Z., Cui Y.K., Hennighausen L., O'Shea J.J., and Hunter C.A. Helper T cell IL-2 production is limited by negative feedback and STAT-dependent cytokine signals. J. Exp. Med. 204 (2007) 65-71
56. Waldmann H., Adams E., Fairchild P., and Cobbold S. Infectious tolerance and the long-term acceptance of transplanted tissue. Immunol. Rev. 212 (2006) 301-313
57. Wei S., Kryczek I., Edwards R.P., Zou L., Szeliga W., Banerjee M., Cost M., Cheng P., Chang A., Redman B., et al. Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma. Cancer Res. 67 (2007) 7487-7494
58. Yamanouchi J., Rainbow D., Serra P., Howlett S., Hunter K., Garner V.E., Gonzalez-Munoz A., Clark J., Veijola R., Cubbon R., et al. Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nat. Genet. 39 (2007) 329-337
59. Yang J.C., Sherry R.M., Steinberg S.M., Topalian S.L., Schwartzentruber D.J., Hwu P., Seipp C.A., Rogers-Freezer L., Morton K.E., White D.E., et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. 21 (2003) 3127-3132
60. You S., Belghith M., Cobbold S., Alyanakian M.A., Gouarin C., Barriot S., Garcia C., Waldmann H., Bach J.F., and Chatenoud L. Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells. Diabetes 54 (2005) 1415-1422
61. Yu P., Lee Y., Liu W., Krausz T., Chong A., Schreiber H., and Fu Y.X. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J. Exp. Med. 201 (2005) 779-791